Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver

International Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 767-771

  Slooter, Gerrit D ^a   Breeman, Wouter A P ^a   Marquet, Richard L ^a   Krenning, Eric P ^a   Van Euck, Casper H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LIVER METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR CELL LINE; TUMOR MODEL;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; INDIUM RADIOISOTOPES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OCTREOTIDE; PENTETIC ACID; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; RATS, INBRED STRAINS; RECEPTORS, SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 0032926897     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990531)81:5<767::AID-IJC17>3.0.CO;2-T     Document Type: Article

References (33)

1. ADELSTEIN, S.J., The Auger process: a therapeutic promise? Amer. J. Roentgenol., 160, 707-713 (1993).
2. 1-octreotide. J. nucl. Med., 37, 2002-2006 (1996).
3. 1]octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life. Sci., 49, 1583-1591 (1991).
4. BAMBYREK, W., CRASEMAN, B. and FINK, R.W., X-ray fluorescence yields Auger and Coster-Kronig transition probabilities. Rev. Phys., 44, 716-813 (1972).
5. 1]octreotide. Europ. J. nucl. Med., 21, 328-335 (1994).
6. 1]octreotide. Europ. J. nucl. Med., 22, 609-616 (1995).
7. DUNCAN, J.R., STEPHENSON, M.T., WU, H.P. and ANDERSON, C.J., Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal and hepatocyte lysosomes. Cancer Res., 57, 659-671 (1997).
8. 1-octreotide in midgut carcinoid syndrome. J. nucl. Med., 37, 1519-1521 (1996).
9. HOFLAND, L.J. and LAMBERTS, S.W.J., Somatostatin analogs and receptors: diagnostic and therapeutic applications. In: A. Arnold (ed), Endocrine neoplasms, pp. 365-382, Kluwer, Dordrecht (1997).
10. 3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology, 136, 3698-3706 (1995).
11. HOFLAND, L.J., VISSER-WISSELAAR, H.A. and LAMBERTS, S.W.J., Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. Biochem. Pharmacol., 50, 287-297 (1995).
12. HOWELL, R.W., Radiation spectra for Auger electron emitting radionuclides: report no 2 of AAPM nuclear medicine task group. Med. Phys., 19, 1371-1383 (1992).
13. KRENNING, E.P., BAKKER, W.H., BREEMAN, W.A.P., KOPER, J.W., KOOIJ, P.P.M., AUSEMA, L., LAMERIS, J.S. and LAMBERTS, S.W.J., Localization of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet, 1, 242-244 (1989).
14. 3]octreotide. J. nucl. Med., 33, 652-658 (1992).
15. KRENNING, E.P., DE JONG, M., KOOIJ, P.P.M., BREEMAN, W.A.P., BAKKER, W.H., DE HERDER, W.W., VAN EIJCK, C.H.J., KWEKKEBOOM, D.J., JAMER, F., PAUWELS, S. and VALKEMA, R., Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann. Oncol. (1999). (In press).
16. 1]octreotide; a case history. Ann. N.Y. Acad. Sci., 733, 496-506 (1994).
17. KRENNING, E.P., KOOIJ, P.P.M., PAUWELS, S., BREEMAN, W.A.P., POSTEMA, P.T., DE HERDER, W.W., VALKEMA, R. and KWEKKEBOOM, D.J., Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion, 57(Suppl. 1), 57-61 (1996).
18. 3]octreotide: the Rotterdam experience with more than 1000 patients. Europ. J. nucl. Med., 20, 716-731 (1993).
19. KUBOTA, A., YAMADA, Y., KAGIMOTO, S., SHIMATSU, A., IMAMURA, M., TSUDA, K., IMURA, H., SEINO, S. and SEINO, Y., Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analog SMS 201-995 in treatment of human endocrine tumors. J. clin. Invest., 93, 1321-1325 (1994).
20. KVOLS, L.K., MOERTEL, C.G., O'CONNELL, M.J., SCHUTT, A.J., RUBIN, J. and HAHN, R.G., Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N. Engl. J. Med., 315, 663 (1986).
21. LAMBERTS, S.W.J., KRENNING, E.P. and REUBI, J.C., The role of somatostatin and its analogues in the diagnosis and treatment of tumors. Endocrinol. Rev., 12, 450-482 (1991).
22. NOTT, D.M., BAXTER, J.N., GRIME, J.S., DAY, D.W., COOKE, T.G. and JENKINS, S.A., Effects of a somatostatin analogue (SMS 201-995) on the growth and development of hepatic tumour derived by intraportal injection of Walker cells in rats. Brit. J. Surg., 76, 1149-1151 (1989).
23. REICHLIN, S., Somatostatin. N. Engl. J. Med., 309, 1556-1563 (1983).
24. REUBI, J.C., KRENNING, E.P., LAMBERTS, S.W.J. and KVOLS, L.K., In vitro detection of somatostatin receptors in human tumours. Metabolism, 41, 104-110 (1992).
25. REUBI, J.C., LAISSUE, J., KRENNING, E.P. and LAMBERTS, S.W.J., Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J. Steroid Biochem. mol. Biol., 43, 27-35 (1992).
26. SCHALLY, A.V., Oncological applications of somatostatin analogues. Cancer Res., 48, 6977-6985 (1988).
27. SMITH, J.P. and SOLOMON, T.E., Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology, 95, 1541-1548 (1988).
28. STOLZ, B., SMITH-JONES, P., ALBERT, R., TOLCSVAI, L., BRINER, U., RUSER, G., MACKE, H., WECKBECKER, G. and BRUNS, C., Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer. Digestion, 57, 17-21 (1996).
29. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Europ. J. nucl. Med., 25, 668-674 (1998).
30. VAN EIJCK, C.H.J., SLOOTER, G.D., HOFLAND, L.J., KORT, W., JEEKEL, J., LAMBERTS, S.W.J. MARQUET, R.L., Somatostatin receptor-dependent growth inhibition of liver metastases by octreotide. Brit. J. Surg., 81, 1333-1337 (1994).
31. VIKIC-TOPIC, S., RAISCH, K.P., KVOLS, L.K. and VOK-PAVLOVIC, S., Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J. clin. Endocrinol. Metab., 80, 2974-2979 (1995).
32. WISEMAN, G.A. and KVOLS, L.K., Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin. nucl. Med., 25, 272-278 (1995).
33. 188Re-RC-160, a directly-radiolabelled somatostatin analogue. Int. J. Cancer, 65, 214-220 (1996).